BACKGROUND: Cardiovascular disease (CVD) rates are increased in HIV. The degree to which myocyte injury, strain, and fibrosis occur prior to clinical disease and relate to coronary plaque in HIV is unknown. OBJECTIVE: To investigate newer cardiac biomarkers of subclinical myocyte injury [high-sensitivity troponin T (hs-cTnT)], strain (amino terminal proB-type natriutretic peptide), fibrosis (soluble ST2, Galectin-3), and vascular inflammation (oxidized LDL, lipoprotein-associated phospholipase A2) in HIV-infected individuals and non-HIV controls and relate these to coronary plaque by cardiac computed tomography angiography. DESIGN: Observational. METHODS: Markers were investigated in 155 HIV-infected and 70 non-HIV-infected participants without known CVD and with low traditional CVD risk and related to cardiac computed tomography angiography data. RESULTS: Age, sex, and race did not differ between the groups. Hs-cTnT [3.1 (3.0, 6.4) vs. 3.0 (3.0, 4.0) ng/l, P = 0.03], Galectin-3 [13.5 (10.6, 18.1) vs. 11.6 (9.9, 14.5) ng/ml, P = 0.002], and soluble ST2 [31.5 (24.5, 41.5) vs. 28.3 (20.2, 33.5) ng/ml, P = 0.01] were significantly higher in HIV-infected participants vs. CONTROLS: Detectable hs-cTnT (seen in 50% of HIV participants) related to the overall presence of plaque [odds ratio (OR) 2.3, P = 0.01] and particularly to coronary calcium (OR for Agatston calcium score > 0, 3.3, P = 0.0008 and OR for calcified plaque 7.4, P = 0.01) in HIV, but not in non-HIV. CONCLUSION: Subclinical myocyte injury is observed among young, asymptomatic HIV-infected individuals with low traditional cardiac risk factors. In the setting of HIV infection, the presence of detectable cardiac troponin is strongly associated with coronary plaque, particularly calcified plaque among an asymptomatic group. Future studies are needed to assess if early subclinical injury marked by hs-cTnT predicts plaque progression and cardiac events in HIV.
BACKGROUND:Cardiovascular disease (CVD) rates are increased in HIV. The degree to which myocyte injury, strain, and fibrosis occur prior to clinical disease and relate to coronary plaque in HIV is unknown. OBJECTIVE: To investigate newer cardiac biomarkers of subclinical myocyte injury [high-sensitivity troponin T (hs-cTnT)], strain (amino terminal proB-type natriutretic peptide), fibrosis (soluble ST2, Galectin-3), and vascular inflammation (oxidized LDL, lipoprotein-associated phospholipase A2) in HIV-infected individuals and non-HIV controls and relate these to coronary plaque by cardiac computed tomography angiography. DESIGN: Observational. METHODS: Markers were investigated in 155 HIV-infected and 70 non-HIV-infectedparticipants without known CVD and with low traditional CVD risk and related to cardiac computed tomography angiography data. RESULTS: Age, sex, and race did not differ between the groups. Hs-cTnT [3.1 (3.0, 6.4) vs. 3.0 (3.0, 4.0) ng/l, P = 0.03], Galectin-3 [13.5 (10.6, 18.1) vs. 11.6 (9.9, 14.5) ng/ml, P = 0.002], and soluble ST2 [31.5 (24.5, 41.5) vs. 28.3 (20.2, 33.5) ng/ml, P = 0.01] were significantly higher in HIV-infectedparticipants vs. CONTROLS: Detectable hs-cTnT (seen in 50% of HIV participants) related to the overall presence of plaque [odds ratio (OR) 2.3, P = 0.01] and particularly to coronary calcium (OR for Agatston calcium score > 0, 3.3, P = 0.0008 and OR for calcified plaque 7.4, P = 0.01) in HIV, but not in non-HIV. CONCLUSION: Subclinical myocyte injury is observed among young, asymptomatic HIV-infected individuals with low traditional cardiac risk factors. In the setting of HIV infection, the presence of detectable cardiac troponin is strongly associated with coronary plaque, particularly calcified plaque among an asymptomatic group. Future studies are needed to assess if early subclinical injury marked by hs-cTnT predicts plaque progression and cardiac events in HIV.
Authors: Sibel Altintas; Eline P M Cardinaels; Mathijs O Versteylen; Ivo A Joosen; Milan Seifert; Joachim E Wildberger; Harry J Crijns; Patricia J Nelemans; Marja P Van Dieijen-Visser; Alma M A Mingels; Marco Das; Bas L Kietselaer Journal: J Cardiovasc Comput Tomogr Date: 2015-10-10
Authors: James L Januzzi; Fabian Bamberg; Hang Lee; Quynh A Truong; John H Nichols; Mahir Karakas; Asim A Mohammed; Christopher L Schlett; John T Nagurney; Udo Hoffmann; Wolfgang Koenig Journal: Circulation Date: 2010-03-01 Impact factor: 29.690
Authors: Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Caitlin A Murphy; Kathleen V Fitch; Meghan Feldpausch; Patrick Maehler; Kimberly Wong; Martin Torriani; Gail K Adler; Steven K Grinspoon; Suman Srinivasa Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: Chris deFilippi; Janet Lo; Robert Christenson; Ida Grundberg; Lauren Stone; Markella V Zanni; Hang Lee; Steven K Grinspoon Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Suman Srinivasa; Kathleen V Fitch; Martin Torriani; Markella V Zanni; Christopher Defilippi; Robert Christenson; Patrick Maehler; Sara E Looby; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah Journal: JAMA Date: 2022-09-13 Impact factor: 157.335
Authors: Michael H Chung; Anoop Sv Shah; Hassan Adan Ahmed; Jeilan Mohamed; Isaiah G Akuku; Kuan Ken Lee; Shirjel R Alam; Pablo Perel; Jasmit Shah; Mohammed K Ali; Sherry Eskander Journal: BMJ Open Date: 2022-06-06 Impact factor: 3.006
Authors: Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald Journal: J Card Fail Date: 2018-03-02 Impact factor: 5.712
Authors: Christopher deFilippi; Robert Christenson; Jessica Joyce; Elli A Park; Ashley Wu; Kathleen V Fitch; Sara E Looby; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Janet Lo Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Parker Foster; Lori Sokoll; Ji Li; Gary Gerstenblith; Elliot K Fishman; Thomas Kickler; Shaoguang Chen; Hong Tai; Hong Lai; Shenghan Lai Journal: Int J STD AIDS Date: 2018-10-31 Impact factor: 1.359
Authors: Faisal Rahman; Zhenyu Zhang; Di Zhao; Matthew J Budoff; Frank J Palella; Mallory D Witt; Rhobert W Evans; Lisa P Jacobson; Frederick K Korley; Eliseo Guallar; Wendy S Post; John W McEvoy Journal: J Appl Lab Med Date: 2019-04-23